Denali Therapeutics
Stock Forecast, Prediction & Price Target
Denali Therapeutics (DNLI) stock Price Target by analysts
$40
Potential upside: 170.27%
Denali Therapeutics price prediction
What is Denali Therapeutics stock analysts` prediction?
Denali Therapeutics stock forecast: Based on 2 Wall Street analysts` predicted price targets for Denali Therapeutics in the last 3 months, the avarage price target is $40, with a high forecast of $NaN. The average price target represents a 170.27% change from the last price of $14.8.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Denali Therapeutics stock Price Target by analysts
Full breakdown of analysts given Denali Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Michael Yee Jefferies | 0% 0/1 | 11 months ago | $45 204.05% upside | $27.05 | StreetInsider | Previous targets (0) |
Thomas Shrader BTIG | 0% 0/1 | 12 months ago | $35 136.48% upside | $28 | StreetInsider | Previous targets (0) |
Tazeen Ahmad Bank of America Securities | 0% 0/1 | about 1 year ago | $29 95.94% upside | $25.12 | TheFly | Previous targets (0) |
Paul Mattels Stifel Nicolaus | 0% 0/1 | about 1 year ago | $22 48.64% upside | $25.12 | StreetInsider | Previous targets (0) |
Salveen Richter Goldman Sachs | 0% 0/2 | about 1 year ago | $46 210.81% upside | $25.12 | StreetInsider | Previous targets (1) |
Marank Mamtani B.Riley Financial | 0% 0/1 | about 1 year ago | $33 122.97% upside | $25.12 | StreetInsider | Previous targets (0) |
Salveen Richter Goldman Sachs | 0% 0/2 | about 4 years ago | $112 656.75% upside | $52.93 | StreetInsider | Previous targets (1) |
Esther Rajavelu UBS | 100% 1/1 | over 4 years ago | $70 372.97% upside | $55.51 | TheFly | Previous targets (0) |
Denali Therapeutics Financial Estimates
Denali Therapeutics Revenue Estimates
Denali Therapeutics EBITDA Estimates
Denali Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $48.66M N/A | $108.46M 122.89% | $330.53M 204.74% | Avg: $106.65M Low: $61.83M High: $216.27M avg. -67.73% | Avg: $263.82M Low: $149.30M High: $505.82M avg. 147.35% | Avg: $445.38M Low: $252.05M High: $853.93M avg. 68.81% | Avg: $759.60M Low: $429.87M High: $1.45B avg. 70.54% |
Net Income
% change YoY
| $-290.58M N/A | $-325.99M -12.18% | $-145.22M 55.45% | Avg: $-464.19M Low: $-456.07M High: $-179.95M avg. -219.64% | Avg: $-394.53M Low: $-471.18M High: $-89.29M avg. 15.00% | Avg: $-129.95M Low: $-284.91M High: $-56.62M avg. 67.06% | Avg: $124.18M Low: $54.10M High: $272.27M avg. 195.56% |
EBITDA
% change YoY
| $-295.75M N/A | $-330.36M -11.70% | $-179.97M 45.52% | Avg: $-71.62M Low: $-145.23M High: $-41.52M avg. 60.20% | Avg: $-177.16M Low: $-339.67M High: $-100.26M avg. -147.35% | Avg: $-299.08M Low: $-573.44M High: $-169.26M avg. -68.81% | Avg: $-510.09M Low: $-978.00M High: $-288.67M avg. -70.54% |
EPS
% change YoY
| -$2.39 N/A | -$2.6 -8.78% | -$1.06 59.23% | Avg: -$2.74 Low: -$3.32 High: -$1.31 avg. -158.11% | Avg: -$2.12 Low: -$3.43 High: -$0.65 avg. 22.44% | Avg: -$0.95 Low: -$2.07 High: -$0.41 avg. 55.41% | Avg: $0.9 Low: $0.39 High: $1.98 avg. 195.56% |
Operating Expenses
% change YoY
| $344.41M N/A | $449.20M 30.42% | $527.23M 17.36% | Avg: $99.03M Low: $57.41M High: $200.82M avg. -81.21% | Avg: $244.98M Low: $138.63M High: $469.70M avg. 147.35% | Avg: $413.57M Low: $234.05M High: $792.95M avg. 68.81% | Avg: $705.35M Low: $399.17M High: $1.35B avg. 70.54% |
FAQ
What is Denali Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 14.49% in 2025-2028.
We have gathered data from 12 analysts. Their low estimate is -456.07M, average is -464.19M and high is -179.95M.
What is Denali Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 54.74% in 2025-2028.
We have gathered data from 11 analysts. Their low revenue estimate is $61.83M, average is $106.65M and high is $216.27M.
What is Denali Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 28.82% in 2025-2028.
We have gathered data from 12 analysts. Their low earnings per share estimate is -$3.32, average is -$2.74 and high is $-1.31.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Denali Therapeutics stock. The most successful analyst is Michael Yee.